Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.
OBJECTIVE
The optimal management of stage I follicular lymphoma, according to consensus guidelines, is based on uncontrolled experiences of select institutions. Diverse treatment approaches are used despite guidelines that recommend radiation therapy (XRT).


METHODS
We analyzed outcomes of patients with stage I follicular lymphoma enrolled onto the National LymphoCare database.


RESULTS
Of 471 patients with stage I follicular lymphoma, 206 patients underwent rigorous staging as defined by both a bone marrow aspirate and biopsy and an imaging study (a computed tomography [CT] scan of the whole body, a positron emission tomography [PET]/CT scan, or both). Rigorously staged patients had superior progression-free survival (PFS) compared with nonrigorously staged patients (hazard ratio [HR], 0.63). Treatments given to rigorously staged patients were rituximab/chemotherapy (R-chemo; 28%), XRT (27%), observation (17%), systemic therapy + XRT (13%), rituximab monotherapy (12%), and other (3%). With a median follow-up of 57 months for PFS, there were 44 progression events (in 21% of patients) for rigorously staged patients. For these patients, PFS was significantly improved with either R-chemo or systemic therapy + XRT compared with patients receiving XRT alone after adjustment for histology, LDH, and the presence of B symptoms. There were no differences in overall survival.


CONCLUSIONS
In this largest, prospectively enrolled group of patients with stage I follicular lymphoma, variable treatment approaches resulted in similar excellent outcomes, which challenges the paradigm that XRT should be standard for this presentation.
University of Rochester, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA. jonathan_friedberg@urmc.rochester.edu
Jonathan W
JW
Friedberg
Michelle
M
Byrtek
Brian K
BK
Link
Christopher
C
Flowers
Michael
M
Taylor
John
J
Hainsworth
James R
JR
Cerhan
Andrew D
AD
Zelenetz
Jamie
J
Hirata
Thomas P
TP
Miller
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D019983:Guideline Adherence; D006801:Humans; D008224:Lymphoma, Follicular / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D012042:Registries / Q000706:statistics & numerical data; D000069283:Rituximab; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab